One-year results from the global utilization of streptokinase and TPA for occluded coronary arteries (GUSTO-I) trial

Circulation

Volumn 94, Issue 6, 1996, Pages 1233-1238

  Califf, Robert M ^a   White, Harvey D ^b   Van de Werf, Frans ^h   Sadowski, Zygmunt ^c   Armstrong, Paul W ^d   Vahanian, Alec ^e   Simoons, Maarten L ^f   Simes, R John ^g   Lee, Kerry L ^a   Topol, Eric J ⁱ  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GREEN LANE HOSPITAL   (New Zealand)

^c INSTITUTE OF CARDIOLOGY   (Poland)

^d UNIVERSITY OF ALBERTA   (Canada)

^e HÔPITAL TENON   (France)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF SYDNEY   (Australia)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

follow up studies; mortality; myocardial infarction; thrombolysis

Indexed keywords

ALTEPLASE; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

EID: 9544219698     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.6.1233     Document Type: Article

References (24)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
2. Third International Study of Infarct Survival (ISIS) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1993;339:753-770.
3. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET Study - Anglo-Scandinavian Study of Early Thrombolysis. Lancet. 1990;335:1175-1178.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
5. AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. Lancet. 1990;335:427-431.
6. Van de Werf F. Thrombolysis for acute myocardial infarction: why is there no extra benefit after hospital discharge? Circulation. 1995;91:2862-2864.
7. Simoons ML, Vos J, Tijssen JG, Vermeer F, Verheugt FW, Krauss XH, Cats VM. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. J Am Coll Cardiol 1989;14:1609-1615.
8. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet. 1987;2:871-874.
9. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Six-month survival in 20,891 patients with acute myocardial infarction randomised between alteplase and streptokinase with or without heparin: GISSI-2 and International Study Group. Eur Heart J. 1992;13:1692-1697.
10. Baigent C, Collins R, for the ISIS Collaborative Group. ISIS-2: 4-year mortality follow-up of 17 187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction. Circulation. 1993;88(suppl I):I-291. Abstract.
11. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
12. Berkson J. The calculation of survival rates. In: Walters W, Gray HK, Priestly JT, eds. Carcinoma and Other Malignant Lesions of the Stomach. Philadelphia, Pa: WB Saunders Co; 1942.
13. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, Califf RM, for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients. Circulation. 1995;91:1659-1668.
14. Gore JM, Granger CB, Simoons ML, Sloan MA, Weaver D, White HD, Barbash GI, Van de Werf F, Aylward PE, Topol EJ, Califf RM, for the GUSTO-I Investigators. Stroke after thrombolytic therapy: mortality and functional outcomes in the GUSTO-I trial. Circulation. 1995;92:2811-2818.
15. The GUSTO-I Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
16. Ross AM, Cho S, Lundergan C, Reiner J, Simoons M, Van de Werf F, Coyne K, Califf R, Topol E. The survival advantage of early grade 3 patency after thrombolysis for infarction increases over time. J Am Coll Cardiol. 1995;25:6A-7A. Abstract.
17. Newby LK, Califf RM, Guerci A, Weaver WD, Col J, Morgan JH, Mark DB, Stebbins A, Van de Werf F, Gore JM, Topol EJ, for the GUSTO Investigators. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the GUSTO trial. J Am Coll Cardiol 1996;27:625-632.
18. Gilpin EA, Koziol JA, Madsen EB, Henning H, Ross J Jr. Periods of differing mortality distribution during the first year after acute myocardial infarction. Am J Cardiol. 1983;52:240-244.
19. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after myocardial infarction. Lancet. 1994;343:1115-1122.
20. Califf RM, Bengtson JR. Cardiogenic shock. N Engl J Med. 1994;330:1724-1730.
21. Becker RC. Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock. Am Heart J. 1993;125:919-929.
22. Califf RM, for the GUSTO Investigators. The use of coronary artery bypass grafting in the GUSTO trial. Circulation. 1994;90(suppl I):I-434. Abstract.
23. Lee KL, Califf RM, Simes RJ, Van de Werf F, Topol EJ, for the GUSTO Investigators. Holding GUSTO up to the light. Ann Intern Med. 1994;120:876-881.
24. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, Barbash G, White H, Simoons ML, Nelson CL, Clapp-Channing N, Knight JD, Harrell FE Jr, Simes J, Topol EJ. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-1424.